Khiron Life Sciences (CVE:KHRN) Potential Beneficiary of Mercosur European Trade Deal
Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) has welcomed the recently announced trade deal between the European Union and Mercosur, effectively titled EU-Mercosur Trade Agreement. Subject to ratification by member countries, the agreement establishes a framework to promote free trade and fluid movement of goods and services which includes pharmaceutical and medical products. HELLO CANNABIS!
How Does Khiron Benefit?
Mercosur is a trading bloc comprised of Argentina, Brazil, Paraguay, and Uruguay plus several associate members. The population of all associated members amounts to nearly 780 million people encompassing almost a quarter of the world’s GDP. According to the European Commission, the trade deal announced at the G20 Summit in Japan is estimated to see upwards of 88 Billion Euros traded in goods from the Mercosur nations.
Khiron is active within the Mercosur jurisdictions, recently completing the acquisition of NettaGrowth International, a cannabis company based in Uruguay. NettaGrowth, and its wholly-owned subsidiary Dormul S.A. obtained one of the first licences to produce and export medical cannabis with THC for commercialization in Uruguay, and through the Mercosur agreement are positioned to serve Brazil and the growing Latin American market. The acquisition of NettaGrowth provides Khiron with up to an additional 120 tonnes of licensed production capacity and diversifies Khiron´s licence composition to include medical use and flower cultivation distribution capabilities.
Khiron Life Sciences President Chris Naprawa on definitive agreement to acquire NettaGrowth
“We welcome this trade deal as it strengthens our ability to now directly supply the European medical cannabis market”. – Alvaro Torres, Khiron Life Sciences CEO & Director
Khiron has made quite a number of impressive moves this year. With an expanding global footprint, they are positioned to become a dominant MCO, Multi Country Operator.
Midas Letter will follow this story closely with great interest.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.